CSS
DNLI icon

Cubist Systematic Strategies’s Denali Therapeutics DNLI Stock Holding History

Cubist Systematic Strategies’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.35M Sell
230,968
-165,618
-42% -$2.38M 0.02% 1236
2025
Q2 		$5.55M Buy
+396,586
New +$5.58M 0.03% 956
2024
Q1 		– Sell
-77
Closed -$1.65K – 3851
2023
Q4 		$1.65K Buy
+77
New +$1.52K ﹤0.01% 3460
2023
Q3 		– Sell
-26,642
Closed -$786K – 3465
2023
Q2 		$786K Sell
26,642
-65,164
-71% -$1.83M 0.01% 2105
2023
Q1 		$2.12M Buy
91,806
+86,966
+1,797% +$2.39M 0.01% 1626
2022
Q4 		$135K Sell
4,840
-33,501
-87% -$997K ﹤0.01% 3733
2022
Q3 		$1.18M Sell
38,341
-33,563
-47% -$1.09M 0.01% 2483
2022
Q2 		$2.12M Buy
71,904
+55,735
+345% +$1.46M 0.01% 1801
2022
Q1 		$520K Buy
16,169
+8,303
+106% +$286K ﹤0.01% 2515
2021
Q4 		$351K Sell
7,866
-1,740
-18% -$82.4K ﹤0.01% 2694
2021
Q3 		$485K Sell
9,606
-5,462
-36% -$308K 0.01% 2057
2021
Q2 		$1.18M Sell
15,068
-68,573
-82% -$4.24M 0.01% 1444
2021
Q1 		$4.78M Buy
83,641
+62,192
+290% +$4.16M 0.06% 480
2020
Q4 		$1.8M Sell
21,449
-66,120
-76% -$4M 0.02% 1016
2020
Q3 		$3.14M Buy
87,569
+66,979
+325% +$2.02M 0.05% 636
2020
Q2 		$498K Sell
20,590
-2,909
-12% -$68.4K 0.01% 1591
2020
Q1 		$411K Buy
+23,499
New +$490K 0.01% 1348
2019
Q2 		– Sell
-20,840
Closed -$484K – 2476
2019
Q1 		$484K Buy
+20,840
New +$436K 0.02% 1217
2018
Q1 		– Sell
-11,775
Closed -$184K – 1882
2017
Q4 		$184K Buy
+11,775
New +$212K 0.01% 1555

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cubist Systematic Strategies's DNLI Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Denali Therapeutics (DNLI) stake by 42% in Q3 2025, selling an estimated $2.38M and leaving 230,968 shares worth $3.35M. The position accounts for 0.02% of the portfolio, ranked #1236.

Cubist Systematic Strategies first reported a position in DNLI in Q4 2017 and has held it in 19 quarters since. The position peaked at $5.55M in Q2 2025. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Cubist Systematic Strategies held 230,968 shares of Denali Therapeutics worth $3.35M as of Q3 2025.
  • Cubist Systematic Strategies sold 165,618 Denali Therapeutics shares in Q3 2025, an estimated $2.38M.
  • Denali Therapeutics made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1236 holding.
  • Cubist Systematic Strategies first reported a position in Denali Therapeutics in Q4 2017 and has held it in 19 quarters since.
  • Cubist Systematic Strategies's Denali Therapeutics position peaked at $5.55M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.